triazoles has been researched along with carfilzomib in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Sebestyén, Z; Szabó, B; Szepesi, K | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Kauffman, M; Kraftson, SJ; Maxwell, SP; Mayampurath, A; McCauley, D; Rosebeck, S; Shacham, S; Volchenboum, SL | 1 |
| Hawkes, N | 1 |
| Bauer, AA; Dai, Y; Dawson, JL; Gomez, J; Grant, S; Kashyap, T; Landesman, Y; Meads, M; Shain, KH; Sullivan, DM; Turner, JG | 1 |
| Musi, E; Nair, JS; Schwartz, GK | 1 |
| Bajpai, R; Hall, WD; Lonial, S; Qian, G; Shanmugam, M; Sun, SY; Yao, W; Zhang, S | 1 |
| Chari, A; Cole, CE; Hycner, T; Jakubowiak, AJ; Jasielec, JK; Karrison, T; McIver, A; Mikhael, J; Nam, J; Rosebeck, S; Rosenbaum, CA; Severson, E; Stephens, LA; Tinari, K; Turowski, A; Zimmerman, TM; Zonder, JA | 1 |
| Potluri, A; Radhakrishnan, SK; Vangala, JR | 1 |
| Dakle, P; Jeitany, M; Jiang, YY; Kanojia, D; Kappei, D; Koeffler, HP; Landesman, Y; Madan, V; Mukundan, V; Pathak, E; Prabhu, A; Tam, WL | 1 |
| Forsberg, P; Mark, TM; Sherbenou, D; Stalker, M | 1 |
| Ammu, S; Bahlis, NJ; Baljevic, M; Ben-Shahar, O; Bensinger, WI; Bentur, OS; Biran, N; Callander, NS; Chen, CI; DeCastro, A; Gasparetto, C; Kauffman, M; Kotb, R; LeBlanc, R; Lentzsch, S; Lipe, B; Madan, S; Rossi, AC; Schiller, GJ; Sebag, M; Shacham, S; Shah, J; Sutherland, HJ; Tuchman, SA; Van Domelen, D; Venner, CP; White, D; Zhang, C; Zhou, T | 1 |
1 review(s) available for triazoles and carfilzomib
| Article | Year |
|---|---|
[Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antiemetics; Antifungal Agents; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Humans; Hungary; Multiple Myeloma; Oligopeptides; Piperazines; Pyrimidines; Quinolones; Quinuclidines; Solubility; Thiazoles; Triazoles; Voriconazole | 2013 |
2 trial(s) available for triazoles and carfilzomib
| Article | Year |
|---|---|
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prognosis; Recurrence; Retreatment; Treatment Outcome; Triazoles | 2019 |
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Analysis; Translocation, Genetic; Treatment Outcome; Triazoles | 2022 |
8 other study(ies) available for triazoles and carfilzomib
| Article | Year |
|---|---|
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Caspase 10; Caspase 8; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Enzyme Activation; Humans; Hydrazines; Intracellular Space; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Triazoles; Xenograft Model Antitumor Assays | 2016 |
European drug agency launches website giving open access to trial data.
Topics: Access to Information; Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Europe; Gout; Gout Suppressants; Humans; Internet; Multiple Myeloma; Oligopeptides; Thioglycolates; Triazoles | 2016 |
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Oligopeptides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Time Factors; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Survival; Exportin 1 Protein; Humans; Hydrazines; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; Karyopherins; Mice; NF-kappa B; Oligopeptides; Receptors, Cytoplasmic and Nuclear; Sarcoma; Survivin; Transcription Factor RelA; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; HCT116 Cells; Humans; Mice, Nude; Neoplasms; Oligopeptides; Proteasome Inhibitors; Proteins; RNA Interference; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzodiazepines; Cell Death; Cell Line, Tumor; Drug Synergism; Heterocyclic Compounds, 4 or More Rings; Humans; NF-E2-Related Factor 1; Oligopeptides; Proteasome Inhibitors; Triazoles; Unfolded Protein Response | 2020 |
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Fatty Acid Desaturases; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Liposarcoma; Oligopeptides; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Homologous; Treatment Outcome; Triazoles | 2021 |